Cerus (CERS) Cash from Investing Activities (2010 - 2026)
Cerus (CERS) reported Cash from Investing Activities of $9.9 million for Q1 2026, up 929.27% on a YoY basis from $957962.1 in Q1 2025, and up 815.53% sequentially from -$1.4 million in Q4 2025.
Cerus (CERS) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Cerus (CERS) has 17 years of Cash from Investing Activities data on file, last reported at $9.9 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 929.27% year-over-year to $9.9 million; the trailing twelve-month figure through Mar 2026 stood at $4.9 million (up 145.37% YoY), and the FY2025 full-year result was -$6.2 million, up 24.17% from the prior year.
- Cash from Investing Activities advanced to $9.9 million in Q1 2026, from -$1.4 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $9.9 million in Q1 2026 to a low of -$7.3 million in Q4 2024.
- A 5-year average of $744294.1 and a median of -$1.1 million in 2025 frame the typical range for Cash from Investing Activities.
- Peak annual rise in Cash from Investing Activities reached 1851.64% in 2024, while the deepest fall reached 405.15% in 2024.
- Tracing CERS's Cash from Investing Activities over 5 years: stood at $7.4 million in 2022, then advanced by 11.28% to $8.2 million in 2023, then slumped by 188.68% to -$7.3 million in 2024, then surged by 81.09% to -$1.4 million in 2025, then soared by 815.53% to $9.9 million in 2026.
- Business Quant data shows CERS's Cash from Investing Activities at $9.9 million in Q1 2026, -$1.4 million in Q4 2025, and -$2.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Cerus | 600.87 Mn | 520.44 Mn | 27.89 Mn | 9.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.86 Mn |
| Mar 31, 2026 | 9.86 Mn |
| Dec 31, 2025 | -1.38 Mn |
| Dec 31, 2025 | -1.38 Mn |
| Sep 30, 2025 | -2.51 Mn |
| Sep 30, 2025 | -2.51 Mn |
| Jun 30, 2025 | -1.09 Mn |
| Jun 30, 2025 | -1.09 Mn |
| Mar 31, 2025 | -1.19 Mn |
| Mar 31, 2025 | -1.19 Mn |
| Dec 31, 2024 | -7.29 Mn |
| Dec 31, 2024 | -7.29 Mn |
| Sep 30, 2024 | 4.82 Mn |
| Sep 30, 2024 | 4.82 Mn |
| Jun 30, 2024 | -7.11 Mn |
| Jun 30, 2024 | -7.11 Mn |
| Mar 31, 2024 | 1.45 Mn |
| Mar 31, 2024 | 1.45 Mn |
| Dec 31, 2023 | 8.22 Mn |
| Dec 31, 2023 | 8.22 Mn |